Skip to Content

Combination therapy shows promising results in newly diagnosed multiple myeloma patients

An overall response of 100% with isatuximab plus carfilzomib, lenalidomide and dexamethasone and a progression free survival rate for the first 50 patients of 79.6% and 75.5% after 12 and 24 months are good news for patients with newly diagnosed multiple myeloma.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top